Progress in Investigating the Relationship between Omega-3 Polyunsaturated Fatty Acids and Coronary Heart Disease (CHD)
DOI:
https://doi.org/10.61173/5ynvax54Keywords:
Coronary Heart Disease, Omega-3 Polyunsaturated Fatty Acids, Atherosclerosis, EndothelialAbstract
Coronary heart disease (CHD) is a globally common cardiovascular disorder, characterized by atherosclerotic lesions in the coronary arteries, leading to narrowing or blockage of the vessels, which subsequently causes myocardial ischemia, hypoxia, and even necrosis. This condition significantly impacts the daily life of patients and represents a major contributor to both morbidity and mortality on a global scale. Omega-3 polyunsaturated fatty acids (ω-3 PUFA), Principally extracted from marine pisces and certain plants, have been increasingly shown in recent years to be closely associated with various pathophysiological mechanisms related to CHD, which holds significant value in the prevention and treatment of CHD. This review offers a comprehensive summary of the sources of ω-3 PUFA, explores the pathophysiological mechanisms of CHD, and offers an in-depth analysis of the multifaceted contribution of ω-3 PUFA in mitigating the susceptibility to CHD, particularly focusing on their effects on lipid metabolism, endothelial function, and inflammatory pathways, thereby contributing new research perspectives for the tactics for the risk mitigation and administration of CHD, including both preventive measures and therapeutic interventions.
References
[1] Martin, Seth S., et al. “2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association.” Circulation 149.8 (2024): e347-e913.
[2] Jayedi, Ahmad, Mahdieh Sadat Zargar, and Sakineh Shab- Bidar. “Fish consumption and risk of myocardial infarction: a systematic review and dose-response meta-analysis suggests a regional difference.” Nutrition Research 62 (2019): 1-12.
[3] Innes, Jacqueline K., and Philip C. Calder. “Marine omega-3 (N-3) fatty acids for cardiovascular health: an update for 2020.” International journal of molecular sciences 21.4 (2020): 1362.
[4] Morgan, John, et al. “High-density lipoprotein subfractions and risk of coronary artery disease.” Current atherosclerosis reports 6.5 (2004): 359-365.
[5] Karalis, Dean G. “A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids.” Advances in therapy 34 (2017): 300-323. Dean&Francis
[6] Davignon, Jean, and Peter Ganz. “Role of endothelial dysfunction in atherosclerosis.” Circulation 109.23_suppl_1 (2004): III-27.
[7] Ross, Russell. “The pathogenesis of atherosclerosis: a perspective for the 1990s.” Nature 362.6423 (1993): 801-809.
[8] Calder, Philip C. “Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance.” Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1851.4 (2015): 469-484.
[9] Rask-Madsen, C., & King, G. L. (2013). Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metabolism, 17(1), 20-33.
[10] [Libby, Peter. “Inflammation in atherosclerosis.” Arteriosclerosis, thrombosis, and vascular biology 32.9 (2012): 2045-2051.
[11] [Ridker, Paul M. “From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection.” Circulation research 118.1 (2016): 145-156.
[12] Zhang Fengmei, et al. “Study on the correlation between polyunsaturated fatty acid ω-3/polyunsaturateed fatty acid ω-6 and coronary artery disease” Shannxi Medical Journal 52.10 (2023): 1326-1330.
[13] O’Keefe, James H., Dany Jacob, and Carl J. Lavie. “Omega-3 fatty acid therapy: the tide turns for a fish story.” Mayo Clinic Proceedings. Vol. 92. No. 1. Elsevier, 2017.
[14] O’Keefe, Evan L., et al. “Sea change for marine omega-3s: randomized trials show fish oil reduces cardiovascular events.” Mayo Clinic Proceedings. Vol. 94. No. 12. Elsevier, 2019.
[15] Siscovick, David S., et al. “Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.” Jama 274.17 (1995): 1363-1367.
[16] Albert, Christine M., et al. “Blood levels of long-chain n–3 fatty acids and the risk of sudden death.” New England Journal of Medicine 346.15 (2002): 1113-1118.
[17] Tavazzi, Luigi, et al. “Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) 372.9645 (2008): 1223-1230.
[18] Mozaffarian, Dariush, and Jason HY Wu. “Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.” Journal of the American College of Cardiology 58.20 (2011): 2047-2067.
[19] Maki, Kevin C., et al. “A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).” Clinical therapeutics 35.9 (2013): 1400-1411.
[20] Bhatt, Deepak L., et al. “Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.” New England Journal of Medicine 380.1 (2019): 11-22.
[21] Harris, William S., et al. “Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives.” Atherosclerosis 197.1 (2008): 12-24.
[22] Griffin, Margaret D., et al. “Effects of altering the ratio of dietary n− 6 to n− 3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45–70 y: the OPTILIP Study.” The American journal of clinical nutrition 84.6 (2006): 1290-1298.
[23] Wilkinson, Paul, et al. “Influence of α-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype.” Atherosclerosis 181.1 (2005): 115-124.
[24] Caroprese, Mariangela, et al. “Flaxseed supplementation improves fatty acid profile of cow milk.” Journal of Dairy Science 93.6 (2010): 2580-2588.
[25] Layne, Joseph, et al. “Caveolae: a regulatory platform for nutritional modulation of inflammatory diseases.” The Journal of nutritional biochemistry 22.9 (2011): 807-811.
[26] Cappellari, Gianluca Gortan, et al. “Treatment with n-3 polyunsaturated fatty acids reverses endothelial dysfunction and oxidative stress in experimental menopause.” The Journal of nutritional biochemistry 24.1 (2013): 371-379.
[27] Zhang, Wei, et al. “Alpha-linolenic acid intake prevents endothelial dysfunction in high-fat diet-fed streptozotocin rats and underlying mechanisms.” Vasa 42.6 (2013): 421-428.
[28] Miles, Elizabeth A., Fiona A. Wallace, and Philip C. Calder. “Dietary fish oil reduces intercellular adhesion molecule 1 and scavenger receptor expression on murine macrophages.” Atherosclerosis 152.1 (2000): 43-50.
[29] SANDERSON, and CALDER. “Dietary fish oil diminishes lymphocyte adhesion to macrophage and endothelial cell monolayers.” Immunology 94.1 (1998): 79-87.
[30] De Caterina, Raffaele, et al. “The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells.” Arteriosclerosis and thrombosis: a journal of vascular biology 14.11 (1994): 1829-1836.
[31] Yamada, Hideto, et al. “In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid.” Arteriosclerosis, thrombosis, and vascular biology 28.12 (2008): 2173-2179.
[32] Capó, Xavier, et al. “Resolvins as proresolving inflammatory mediators in cardiovascular disease.” European Journal of Medicinal Chemistry 153 (2018): 123-130.
[33] Calder, Philip C. “Omega-3 Polyunsaturated Fatty Acids and Inflammatory Processes: Nutrition or Pharmacology?” British Journal of Clinical Pharmacology 83 (2017): 105-117.
[34] Bays, Harold E., et al. “Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.” American Journal of Cardiovascular Drugs 13 (2013): 37-46.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
